Please assess the completion status of the following clinical trial:

Trial Title: MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participant has a diagnosis of essential hypertension~* Participant is being treated with a single, or dual combination treatment for hypertension and will be able to discontinue the prior antihypertensive medication~* Participant has a mean trough SiDBP of ≥ 90 mmHg and \< 110 mmHg~* Participant has a mean trough SiSBP of ≥ 140 mmHg and \< 200 mmHg~* Participant has no clinically significant abnormality at screening visit~Exclusion criteria:~* Participant is currently taking \>2 antihypertensive medications~* Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-Lotan or Preminent, amlodipine or dihydropyridine drug and thiazide drug or related drug (i.e., sulfonamide-containing chlortalidone medicines)~* Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence~* Participant is pregnant or breastfeeding, or expecting to conceive OR the pregnancy test is positive at screening visit (Visit 1)~* Participant is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- L50/H12.5/A5→L50/H12.5/A5 (Type: EXPERIMENTAL): One combination tablet containing L50 mg, H12.5 mg, and A5 mg, orally, once daily, for up to 8 weeks (double-blind treatment period). Participants continue with once daily L50/H12.5/A5 for 44 weeks during open label extension.
- L50/H12.5→L50/H12.5/A5 (Type: ACTIVE_COMPARATOR): One combination tablet containing L50 mg and H12.5 mg, orally, once daily, for up to 8 weeks during double-blind treatment period. Participants then receive once daily L50/H12.5/A5 for 44 weeks during open-label extension

Based on this trial design, predict the completion outcome and termination type (if applicable).